Toshiba continues to build management team
Toshiba America Medical Systems has named Scott Eaton director of MRI business unit development. Eaton replaces Steve Sickels, who was appointed senior director of TAMS’ ultrasound unit in April (SCAN 4/28/99). Eaton joined TAMS six years ago
Toshiba America Medical Systems has named Scott Eaton director of MRI business unit development. Eaton replaces Steve Sickels, who was appointed senior director of TAMS ultrasound unit in April (SCAN 4/28/99). Eaton joined TAMS six years ago as senior product manager in the companys CT business unit, and participated in the companys launch of Xpress and Xvision helical CT scanners. In 1997, he joined the MRI business unit and helped the company introduce its OPART open MRI system.
Eatons appointment is the latest in a spate of management shifts at TAMS. Earlier this month, Toshiba named Robert Kreps as vice president, full-line sales, and Steven Oblen as director of ultrasound sales operations and business development (SCAN 10/13/99).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
